Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation

Opko Health Inc. (NASDAQ:OPK) is one of the best high-return penny stocks to buy right now. On February 10, analysts at H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) and settled on a $3 price target. The positive stance underscores the research firm’s confidence amid progress in the company’s biological partnerships.

The company’s subsidiary, OPKO Health, has already expanded its collaboration with Entera Bio to accelerate the development of the first oral, long-acting parathyroid hormone analog for the treatment of hypoparathyroidism. The partnered program showed positive PK/PD results in December 2025, with an IND filing planned for late 2026. OPKO and Entera each hold 50% ownership.

Oral OXM and oral GLP-2 have both demonstrated robust PK profiles and bioavailability. Furthermore, preclinical data of oral LA-PTH suggests that this program holds the potential to transform the hypoparathyroidism landscape, said Miranda Toledano, Chief Executive Officer of Entera.

Under the terms of the strategic collaboration, OPKO and Entera are to hold a 50% pro rata ownership interest in the LA-PTH hypoparathyroidism. The company will also be responsible for 50% of the program’s development costs.

Opko Health Inc. (NASDAQ:OPK) is a diversified healthcare company that operates in two main segments: diagnostics and pharmaceuticals. It operates BioReference Laboratories, one of the nation’s largest clinical labs, and develops drugs for specialized conditions, including RAYALDEE for chronic kidney disease and NGENLA (somatrogon) for growth hormone deficiency.